报价延迟最少15分钟:2025/07/20 18:35 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4156 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.98/-0.58
|
|
企业价值
29.61M
|
| 资产负债 |
|
每股账面净值
-0.08
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.03M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 18:35 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability. |
